Program

Wednesday, June 19

Welcoming Remarks and Keynote Addresses

7:00 p.m.-8:30 p.m.

Transcriptional and epigenetic control of oncogenes
Richard A. Young, MIT Whitehead Institute for Biomedical Research, Cambridge, MA

Varying and poisoning the "Histone Code": A role of the histone variant H3.3 in human cancers
C. David Allis, The Rockefeller University, New York, NY

Opening Reception

8:30 p.m.-10:00 p.m.

Thursday, June 20

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 1: Chromatin Regulators Mutated in Cancer

Session Chairperson: Suzanne J. Baker, St. Jude Children's Research Hospital, Memphis, TN
8:00 a.m.-10:15 a.m.

Effective epigenetic therapy for CIMP positive childhood ependymoma
Michael Taylor, PBTF Institute at Sick Children’s Hospital, Toronto, ON, Canada

ATRX mutations in human carcinogenesis
Nickolas E. Papadopoulos, Johns Hopkins Medical Institutes, Baltimore, MD

Histone H3 mutations in pediatric high-grade gliomas
Suzanne J. Baker

Global chromatin profiling identifies NSD2 mutations in pediatric acute lymphoblastic leukemia*
Frank Stegmeier, Novartis Institute for Biomedical Research, Cambridge, MA

Epigenetics of hormone dependence
Myles Brown, Dana-Farber Cancer Institute, Boston, MA

Break

10:15 a.m.-10:30 a.m.

Session 2: Histone Modifiers

Session Chairperson: Sharon Y.R. Dent, The University of Texas M.D. Anderson Cancer Center, Houston, TX
10:30 a.m.-12:30 p.m.

Epigenetic regulation and heterogeneity in cancer
Bradley E. Bernstein, Massachusetts General Hospital Cancer Center, Boston, MA

New functions for histone modifying enzymes
Sharon Y.R. Dent

Targeting histone methylation in leukemia
Scott A. Armstrong, Memorial Sloan-Kettering Cancer Center, New York, NY

Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects*
Ian Davis, University of North Carolina at Chapel Hill, Chapel Hill, NC

Multivalent histone engagement by the linked tandem Tudor and PHD domains of UHRF1 is required for DNA methylation maintenance*
Scott B. Rothbart, University of North Carolina at Chapel Hill, Chapel Hill, NC

Lunch on Own / Free Time

12:30 p.m.-2:30 p.m.

Session 3: Polycomb Complexes

Session Chairperson: Kristian Helin, University of Copenhagen, Copenhagen, Denmark
2:30 p.m.-4:30 p.m.

Nucleotide biosynthetic enzyme GMP synthase is a relay of p53 stabilization in response to genomic stress
Peter Verrijzer, Erasmus University Medical Center, The Netherlands

Mechanisms regulating polycomb group proteins to target genes
Kristian Helin

The epigenetic stability of pluripotent and somatic cell states
Jacob H. Hanna, The Weizmann Institute of Science, Rehovot, Israel

Genomic and epigenomic interactions of an Ewing sarcoma-specific long noncoding RNA*
Sheetal A. Mitra, Children's Hospital Los Angeles, Los Angeles, CA

Reversing the oncogenic roles of misdirected chromatin remodeling: Disruption of mSWI/SNF (BAF) complexes by the SS18-SSX fusion in human synovial sarcoma*
Cigall Kadoch, Stanford University, Stanford, CA

Poster Session A / Reception

4:30 p.m.-6:30 p.m.

Dinner on Own / Evening Off

6:30 p.m.-

Friday, June 21

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 4: SWI/ SNF (BAF) Complexes

Session Chairperson: Charles W.M. Roberts, Dana-Farber Cancer Institute, Boston, MA
8:00 a.m.-10:00 a.m.

SWI/SNF (BAF) complexes in tumor suppression
Charles W.M. Roberts

Chromatin regulation: New concepts and methods
Gerald R. Crabtree, Stanford University, Stanford, CA

Histone variant H2A.Z sets the stage for ESC differentiation
Keji Zhao, National Institutes of Health, Bethesda, MD

CARM1 methylates BAF155 and perturbs chromatin remodeling machinery to enhance tumor progression*
Wei Xu, University of Wisconsin-Madison, Madison, WI

SNF5 is an essential executor of epigenetic regulation during differentiation*
Minmin Liu, USC Norris Comprehensive Cancer Center, Los Angeles, CA

Break

10:00 a.m.-10:30 a.m.

Session 5: Chromatin Dynamics and Transcriptional Regulation

Session Chairperson: Peter A. Jones, USC Norris Comprehensive Cancer Center, Los Angeles, CA
10:30 a.m.-12:30 p.m.

Reactivating epigenetically silenced genes
Peter A. Jones

mSWI/SNF (BAF) complexes facilitate decatentation of DNA by topoisomerase II*
Emily Dykhuizen, Stanford University, Stanford, CA

Unraveling intricate relationship between chromatin remodeling, transcription, and cancer*
Michael Y. Tolstorukov, Massachusetts General Hospital, Boston, MA

Modulation of chromatin structure and transcription by the SWI/SNF complex in acute lymphoblastic leukemia*
Jennifer Wu, Dana-Farber Cancer Institute, Boston, MA

Doxorubicin enhances nucleosome turnover around active gene promoters*
Fan Yang, Fred Hutchinson Cancer Research Center, Seattle, WA

CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression*
Adrian P. Bracken, Trinity College Dublin, Dublin, Ireland

Poster Session B / Lunch

12:30 p.m.-2:30 p.m.

Session 6: Reprogramming and Development

Session Chairperson: George Q. Daley, Boston Children's Hospital, Harvard Medical School, Boston, MA
2:30 p.m.-4:30 p.m.

The stem cell factor LIN28 in pediatric cancer
George Q. Daley

Genetic and epigenetic control of transcription in hematopoiesis
Stuart H. Orkin, Dana-Farber Cancer Institute, Boston, MA

In vivo RNAi screening for polycomb targets in glioblastoma
Maarten Van Lohuizen, Netherlands Cancer Institute, Amsterdam, The Netherlands

Comparison of the gene regulatory programs controlled by the mutually exclusive SWI/SNF subunits ARID1A and ARID2*
Jesse Raab, University of North Carolina at Chapel Hill, Chapel Hill, NC

Dissecting the role of the histone variant macroH2A in reprogramming and breast cancer*
Alexandre Maia, Icahn School of Medicine at Mount Sinai, New York, NY

Panel Discussion: Inferring Mechanism from Human Genetics and Genomic Analysis of Cancer

Moderator: Gerald R. Crabtree, Stanford University, Stanford, CA
4:30 p.m.-5:30 p.m.

Panelists:

• Jesse J. Smith, Epizyme, Inc., Cambridge, MA
• Charles W.M. Roberts, Dana-Farber Cancer Institute, Boston, MA
• Stuart H. Orkin, Dana-Farber Cancer Institute, Boston, MA

Dinner on Own / Evening Off

5:30 p.m.-

Saturday, June 22

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 7: DNA Methylation

Session Chairperson: Ari M. Melnick, Weill Cornell Medical College, Cornell University, New York, NY
8:00 a.m.-10:00 a.m.

Epigenetic deregulation of gene expression
Ari M. Melnick

Translational implication of DNA methylation changes in the cancer epigenome
Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD

Cancer as a single process of a dysregulated epigenome
Andrew P. Feinberg, Johns Hopkins University School of Medicine, Baltimore, MD

Functional and structural studies of HP1 heterochromatin
Geeta Narlikar, University of California, San Francisco, CA

Break

10:00 a.m.-10:15 a.m.

Session 8: Drugging the Epigenome

Session Chairperson: James E. Bradner, Dana-Farber Cancer Institute, Boston, MA
10:15 a.m.-12:15 p.m.

Histone methyltransferase inhibitors as therapeutic agents in genetically defined cancers
Jessie J. Smith, Epizyme, Inc., Cambridge, MA

Linking genetic features of human cancers and histone-modifying enzymes for future cancer therapies
Stuart L. Schreiber, Howard Hughes Medical Institute, Cambridge, MA

Clinical translation of bromodomain inhibition
James E. Bradner

SUZ12: a novel tumor suppressor and potential biomarker for efficacy of BRD4 inhibition*
Thomas De Raedt, Brigham Women’s Hospital, Boston, MA

A new class of small molecule acetyltransferase inhibitors discovered through high-throughput screening are potent anticancer agents with cancer-type specific activity*
Daiqing Liao, University of Florida College of Medicine, Gainesville, FL

Closing Remarks and Departure

12:15 p.m.-12:30 p.m.